A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds

Tetsuya Yamamoto, Mikiko Takata-Michigami, Yoshiko Hisamatsu, Takenobu Yamamoto, Toshihisa Hamada, Kazuyasu Fujii, Wataru Fujimoto, Koji Taneichi, Yumi Aoyama, Keiji Iwatsuki

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Drug-induced pemphigus is mainly caused by drugs containing sulfhydryl (thiol) groups in their molecules. Objectives: To understand the serial alteration of anti-desmoglein (Dsg) antibody profile in patients with rheumatoid arthritis (RA) receiving thiol compounds. Methods: Anti-Dsg1 or -Dsg3 antibodies were analysed twice in a 1.6-year interval, in the same series of RA patients. Results: Eleven of 204 serum samples (5.4%) and 6 of 139 samples (4.3%) from the same RA group showed a positive reaction against Dsg1 or Dsg3 in the first and second screening tests, respectively. The positive rates were higher than those in patients with collagen diseases including systemic lupus erythematosus, Sjögren syndrome, mixed connective tissue disease, and systemic sclerosis. In comparison with the results in the first and second screening tests, one RA patient newly gained anti-Dsg3 antibody, and at least 4 patients lost the antibodies in 1.6 years. Three patients produced antibodies to Dsg1 and/or Dsg3 in a similar fashion as did in the first screening tests. Only one RA serum sample exhibited an intercellular reactivity to human skin or monkey esophagus by immunofluorescence, and another sample bound to a 130 kDa protein suggestive of Dsg3 by immunoblotting. Most anti-Dsg antibodies in RA patients recognized EDTA-resistant epitopes of Dsg different from EDTA-sensitive epitopes recognized by pemphigus sera. Conclusion: RA patients receiving any of the thiol compounds may gain autoantibodies to non-conformational epitopes of either Dsg1 or Dsg3, and that such autoantibodies alone are not capable of inducing acantholysis.

Original languageEnglish
Pages (from-to)170-175
Number of pages6
JournalJournal of Dermatological Science
Volume59
Issue number3
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Desmogleins
Sulfhydryl Compounds
Anti-Idiotypic Antibodies
Rheumatoid Arthritis
Antibodies
Epitopes
Screening
Edetic Acid
Autoantibodies
Pemphigus
Serum
Acantholysis
Mixed Connective Tissue Disease
Collagen Diseases
Pharmaceutical Preparations
Systemic Scleroderma
Skin
Collagen
Immunoblotting
Systemic Lupus Erythematosus

Keywords

  • Desmoglein
  • Non-pathogenic
  • Pemphigus
  • Rheumatoid arthritis
  • Thiol

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Molecular Biology

Cite this

A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds. / Yamamoto, Tetsuya; Takata-Michigami, Mikiko; Hisamatsu, Yoshiko; Yamamoto, Takenobu; Hamada, Toshihisa; Fujii, Kazuyasu; Fujimoto, Wataru; Taneichi, Koji; Aoyama, Yumi; Iwatsuki, Keiji.

In: Journal of Dermatological Science, Vol. 59, No. 3, 09.2010, p. 170-175.

Research output: Contribution to journalArticle

Yamamoto, T, Takata-Michigami, M, Hisamatsu, Y, Yamamoto, T, Hamada, T, Fujii, K, Fujimoto, W, Taneichi, K, Aoyama, Y & Iwatsuki, K 2010, 'A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds', Journal of Dermatological Science, vol. 59, no. 3, pp. 170-175. https://doi.org/10.1016/j.jdermsci.2010.06.007
Yamamoto, Tetsuya ; Takata-Michigami, Mikiko ; Hisamatsu, Yoshiko ; Yamamoto, Takenobu ; Hamada, Toshihisa ; Fujii, Kazuyasu ; Fujimoto, Wataru ; Taneichi, Koji ; Aoyama, Yumi ; Iwatsuki, Keiji. / A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds. In: Journal of Dermatological Science. 2010 ; Vol. 59, No. 3. pp. 170-175.
@article{9a9e6447423849d9b64b13a83a6afe70,
title = "A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds",
abstract = "Background: Drug-induced pemphigus is mainly caused by drugs containing sulfhydryl (thiol) groups in their molecules. Objectives: To understand the serial alteration of anti-desmoglein (Dsg) antibody profile in patients with rheumatoid arthritis (RA) receiving thiol compounds. Methods: Anti-Dsg1 or -Dsg3 antibodies were analysed twice in a 1.6-year interval, in the same series of RA patients. Results: Eleven of 204 serum samples (5.4{\%}) and 6 of 139 samples (4.3{\%}) from the same RA group showed a positive reaction against Dsg1 or Dsg3 in the first and second screening tests, respectively. The positive rates were higher than those in patients with collagen diseases including systemic lupus erythematosus, Sj{\"o}gren syndrome, mixed connective tissue disease, and systemic sclerosis. In comparison with the results in the first and second screening tests, one RA patient newly gained anti-Dsg3 antibody, and at least 4 patients lost the antibodies in 1.6 years. Three patients produced antibodies to Dsg1 and/or Dsg3 in a similar fashion as did in the first screening tests. Only one RA serum sample exhibited an intercellular reactivity to human skin or monkey esophagus by immunofluorescence, and another sample bound to a 130 kDa protein suggestive of Dsg3 by immunoblotting. Most anti-Dsg antibodies in RA patients recognized EDTA-resistant epitopes of Dsg different from EDTA-sensitive epitopes recognized by pemphigus sera. Conclusion: RA patients receiving any of the thiol compounds may gain autoantibodies to non-conformational epitopes of either Dsg1 or Dsg3, and that such autoantibodies alone are not capable of inducing acantholysis.",
keywords = "Desmoglein, Non-pathogenic, Pemphigus, Rheumatoid arthritis, Thiol",
author = "Tetsuya Yamamoto and Mikiko Takata-Michigami and Yoshiko Hisamatsu and Takenobu Yamamoto and Toshihisa Hamada and Kazuyasu Fujii and Wataru Fujimoto and Koji Taneichi and Yumi Aoyama and Keiji Iwatsuki",
year = "2010",
month = "9",
doi = "10.1016/j.jdermsci.2010.06.007",
language = "English",
volume = "59",
pages = "170--175",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds

AU - Yamamoto, Tetsuya

AU - Takata-Michigami, Mikiko

AU - Hisamatsu, Yoshiko

AU - Yamamoto, Takenobu

AU - Hamada, Toshihisa

AU - Fujii, Kazuyasu

AU - Fujimoto, Wataru

AU - Taneichi, Koji

AU - Aoyama, Yumi

AU - Iwatsuki, Keiji

PY - 2010/9

Y1 - 2010/9

N2 - Background: Drug-induced pemphigus is mainly caused by drugs containing sulfhydryl (thiol) groups in their molecules. Objectives: To understand the serial alteration of anti-desmoglein (Dsg) antibody profile in patients with rheumatoid arthritis (RA) receiving thiol compounds. Methods: Anti-Dsg1 or -Dsg3 antibodies were analysed twice in a 1.6-year interval, in the same series of RA patients. Results: Eleven of 204 serum samples (5.4%) and 6 of 139 samples (4.3%) from the same RA group showed a positive reaction against Dsg1 or Dsg3 in the first and second screening tests, respectively. The positive rates were higher than those in patients with collagen diseases including systemic lupus erythematosus, Sjögren syndrome, mixed connective tissue disease, and systemic sclerosis. In comparison with the results in the first and second screening tests, one RA patient newly gained anti-Dsg3 antibody, and at least 4 patients lost the antibodies in 1.6 years. Three patients produced antibodies to Dsg1 and/or Dsg3 in a similar fashion as did in the first screening tests. Only one RA serum sample exhibited an intercellular reactivity to human skin or monkey esophagus by immunofluorescence, and another sample bound to a 130 kDa protein suggestive of Dsg3 by immunoblotting. Most anti-Dsg antibodies in RA patients recognized EDTA-resistant epitopes of Dsg different from EDTA-sensitive epitopes recognized by pemphigus sera. Conclusion: RA patients receiving any of the thiol compounds may gain autoantibodies to non-conformational epitopes of either Dsg1 or Dsg3, and that such autoantibodies alone are not capable of inducing acantholysis.

AB - Background: Drug-induced pemphigus is mainly caused by drugs containing sulfhydryl (thiol) groups in their molecules. Objectives: To understand the serial alteration of anti-desmoglein (Dsg) antibody profile in patients with rheumatoid arthritis (RA) receiving thiol compounds. Methods: Anti-Dsg1 or -Dsg3 antibodies were analysed twice in a 1.6-year interval, in the same series of RA patients. Results: Eleven of 204 serum samples (5.4%) and 6 of 139 samples (4.3%) from the same RA group showed a positive reaction against Dsg1 or Dsg3 in the first and second screening tests, respectively. The positive rates were higher than those in patients with collagen diseases including systemic lupus erythematosus, Sjögren syndrome, mixed connective tissue disease, and systemic sclerosis. In comparison with the results in the first and second screening tests, one RA patient newly gained anti-Dsg3 antibody, and at least 4 patients lost the antibodies in 1.6 years. Three patients produced antibodies to Dsg1 and/or Dsg3 in a similar fashion as did in the first screening tests. Only one RA serum sample exhibited an intercellular reactivity to human skin or monkey esophagus by immunofluorescence, and another sample bound to a 130 kDa protein suggestive of Dsg3 by immunoblotting. Most anti-Dsg antibodies in RA patients recognized EDTA-resistant epitopes of Dsg different from EDTA-sensitive epitopes recognized by pemphigus sera. Conclusion: RA patients receiving any of the thiol compounds may gain autoantibodies to non-conformational epitopes of either Dsg1 or Dsg3, and that such autoantibodies alone are not capable of inducing acantholysis.

KW - Desmoglein

KW - Non-pathogenic

KW - Pemphigus

KW - Rheumatoid arthritis

KW - Thiol

UR - http://www.scopus.com/inward/record.url?scp=77956178349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956178349&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2010.06.007

DO - 10.1016/j.jdermsci.2010.06.007

M3 - Article

VL - 59

SP - 170

EP - 175

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 3

ER -